Margaret von Mehren

Fox Chase Cancer Center — United States

Medicine · Health Sciences

75h-index33.8kcitations458works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastrointestinal Tumor Research and Treatment(235), Sarcoma Diagnosis and Treatment(189), Gastric Cancer Management and Outcomes(116), Gastrointestinal disorders and treatments(56), Neurofibromatosis and Schwannoma Cases(38)

Publications458 total

Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial
Nature Communications·2025Open Access
DNA Damage Repair Pathway Alterations and Immune Landscape Differences in Pediatric/Adolescent, Young Adult (AYA) and Adult Sarcomas
Cancers·2025· 2 citedOpen Access
Supplemental Figure S2 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplemental Figure S4 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplemental Figure S1 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Data from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplemental Figure S3 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Supplementary Methods 1 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Table S1 from Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
2025Open Access
Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
Journal of Clinical Oncology·2025
SARC044: A phase II trial of bezuclastinib in combination with sunitinib in patients with GIST who progressed on sunitinib monotherapy.
Journal of Clinical Oncology·2025· 1 cited
A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3).
Journal of Clinical Oncology·2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Journal of Clinical Oncology·2025Open Access
ASO Visual Abstract: Examining the Impact of Biopsy Technique on Clinical and Pathologic Outcomes in Dermatofibrosarcoma Protuberans—An International, Multi-Institutional Study
Annals of Surgical Oncology·2025
Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma
Clinical Cancer Research·2025· 1 cited
Examining the Impact of Biopsy Technique on Clinical and Pathologic Outcomes in Dermatofibrosarcoma Protuberans: An International, Multi-Institutional Study
Annals of Surgical Oncology·2025· 2 cited
Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Journal of Clinical Oncology·2025· 1 cited
1764P Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
Annals of Oncology·2024
Current patterns of care and outcomes for dermatofibrosarcoma protuberans: An international multi‐institutional collaborative
Cancer·2024· 5 cited
Palbociclib in Patients With Soft Tissue Sarcoma With <i>CDK4</i> Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study
JCO Precision Oncology·2024· 4 cited
page 1 of 23Next →

Frequent Co-authors

George D. Demetri(24), Charles D. Blanke(15), Michael C. Heinrich(15), Suzanne George(14), Scott M. Schuetze(11), Alberto S. Pappo(11), Robert S. Benjamin(11), Christopher L. Corless(10), Christopher D.�M. Fletcher(10), Robert G. Maki(10), Kristen N. Ganjoo(10), Burton Eisenberg(9), Heikki Joensuu(9), Richard F. Riedel(9), John M. Kane(9), Marilyn M. Bui(8), Sean V. McGarry(8), Annick D. Van den Abbeele(7), Jonathan A. Fletcher(7), Jean‐Yves Blay(7)